ELAN Elanco (ELAN) Q4 FY25 earnings call
Elanco delivered a strong Q4 FY25, driven by 9% organic constant currency revenue growth and significant contributions from new product innovation, particularly Credelio Quattro and Zenrelia. The company exceeded its financial guidance and accelerated deleveraging, positioning it for continued growth and margin expansion in FY26, supported by its "no-regrets" launch strategy and productivity initiatives.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
ELAN operating KPIs by quarter
| KPI | This call Dec 2025 Q4 FY25 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Reorder rate Zenrelia - US | 80%+We're now in about half of the clinics in the US and the reorder rate is over 80%.Source: earnings call transcript | 80%+That's greater than 60% of the total clinic base with a reorder rate maintained at over 80%.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.